A Japanese health ministry proposal to impose steeper price cuts on certain medicines deemed to carry poor cost-effectiveness profiles cleared…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Biogen/Eisai Alzheimer’s Pact Amended to Switch Aducanumab Collab to Royalty Scheme
March 16, 2022
-
ORGANIZATION API Import Costs from Europe Surging amid Russian Airspace Closures
March 15, 2022
-
ORGANIZATION List of 180 Needed Drugs Compiled in Europe-Led Drive to Support Ukraine
March 14, 2022
-
BUSINESS Moderna Accelerating Bivalent Vaccine Development for 4th COVID Shot: Japan Chief
March 14, 2022
-
BUSINESS Fujifilm Drops Avigan’s Japan PIII Trial for COVID-19
March 14, 2022
-
BUSINESS Authorized Generics Likely Speeding Up G1/G2 Price Cuts for Off-Patent Brands: Jiho Tally
March 11, 2022
-
BUSINESS Chugai Won’t Challenge Edirol Substance Patent Ruling
March 11, 2022
-
REGULATORY Panel Confirms Backing for Alexion’s Bleeding Antidote after Data Integrity Issues
March 10, 2022
-
BUSINESS Japan Drug Makers Moving to Support War-Hit Ukraine
March 10, 2022
-
BUSINESS Double-Digit Slashes to Hit 44 Major Drugs in 2022 Price Revision: Top 5 Product Poll
March 9, 2022
-
REGULATORY MHLW Publishes Brand-by-Brand Supply Status for 130 APIs Subject to Its Restriction Lifting Request
March 9, 2022
-
ORGANIZATION Apply Only Market Price-Linked Rules in Next Off-Year Revision, No Hasty Debate for Adjustment Rate: JMA Official
March 8, 2022
-
BUSINESS SanBio’s Sakigake Cell Therapy Finally Filed in Japan for Traumatic Brain Injury
March 8, 2022
-
BUSINESS Eisai Suffers 9%-Plus Cut, Sumitomo Dainippon Over 8% in 2022 Drug Price Revision: Jiho Poll
March 7, 2022
-
REGULATORY Takecab Faces 15.8% Slash, GLP-1s 11.1% in FY2022 Drug Price Revision
March 4, 2022
-
REGULATORY Outgoing Chair of Unapproved Drug Council Boasts 300 Approvals Achieved to Cut Lag, Urges New Reimbursement Scheme
March 4, 2022
-
BUSINESS AZ Japan Working towards 100% Electric Vehicle Fleet by 2025, but Challenges Remain
March 3, 2022
-
REGULATORY Alexion’s Bleeding Antidote Up for PAFSC Discussion Again after Data Integrity Issues
March 3, 2022
-
BUSINESS Zogenix Sees Its Pipeline Drugs Continue to Be Developed in Japan after UCB Deal
March 2, 2022
-
BUSINESS Drugs Might Get Hit by SWIFT Ban on Russia Even If Exempted from Trade Sanctions
March 1, 2022
ページ
A Japanese drug pricing panel on November 11 discussed ways to respond to the US most-favored-nation (MFN) policy, with healthcare…
On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
Japan is set to add 16 new drugs to its NHI reimbursement price list on November 13, including a subcutaneous…
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…